Skip to content
Triangle logo TriangleGet started
← Study library

NCT02389517 · REGISTRY CONDITION SEARCH

Lenalidomide With or Without Ixazomib Citrate and Dexamethasone in Treating Patients With Residual Multiple Myeloma After Donor Stem Cell Transplant

Found through the registry condition index, not selected as a treatment recommendation. This discovery collection was restricted to studies with posted results.

Phase
PHASE2
Status at capture
COMPLETED
Registry last update
2026-01-22

This randomized phase II trial studies how well lenalidomide alone compared to lenalidomide, ixazomib citrate, and dexamethasone work in treating patients with multiple myeloma that remains (residual) after donor stem cell transplant. Lenalidomide may help the immune system kill abnormal blood cells or cancer cells and may also prevent the growth of new blood vessels that are needed for cancer growth. Ixazomib citrate may stop the growth of cancer cells by interfering with proteins necessary for cell growth. Drugs used in chemotherapy, such as dexamethasone, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. It is not yet known whether lenalidomide is more effective with or without ixazomib citrate and dexamethasone in treating residual multiple myeloma.

Open the original ClinicalTrials.gov record → · Download preserved record

What did the study report?

Outcomes, safety and baseline populations are separate source sections. Quality-of-life measures appear under their original outcome titles.

flow

Participant flow

→

baseline

Baseline characteristics

→

outcome · POSTED

Percentage of Participants With MRD Negativity

→

outcome · POSTED

Overall Response (Number of Participants With VGPR, CR, sCR)

→

outcome · POSTED

Duration of MRD-negative Disease

→

outcome · POSTED

Progression Free Survival

→

outcome · POSTED

Overall Survival

→

outcome · POSTED

Number of Patients With Adverse Events

→

outcome · POSTED

Overall Response (Number of Participants With VGPR, CR, sCR)

→

adverse events

Adverse events

→

more info

Limitations, agreements, and source contact

→
Who could take part
eligibility Criteria
Inclusion Criteria: * Patients who completed induction treatment followed by autologous stem cell transplant as initial therapy for symptomatic myeloma as per IMWG criteria and initiated Revlimid (lenalidomide) maintenance * Patients must have initiated lenalidomide maintenance at approximately 3 months post autologous stem transplant (preferably 70-90 but not more than 120 days) * Patients must be receiving lenalidomide 10 mg or 15 mg and be able to tolerate dose escalation to 25 mg daily * Patients must have received lenalidomide maintenance for 3 months (+1 month window for a maximum of 4 months lenalidomide prior to enrollment) * No evidence of progressive disease on lenalidomide * Any measurable residual disease at the time of screening for the study documented in at least one of the following ways: * Serum protein electrophoresis (SPEP)/immunofixation studies (IFIX) positive disease * Freelite only positive disease * SPEP/IFIX - negative and Freelite- negative but MRD-positive disease is allowed * Evidence of MRD at the time of screening for this study by multi-color flow cytometry (bone marrow procedure at screening required) * Bone marrow specimen will be required at study entry; available deoxyribonucleic acid (DNA) sample will be used for calibration step for MRD evaluation by gene sequencing * Life expectancy of more than 3 months * Eastern Cooperative Oncology Group (ECOG) performance status of 0-2 * Bilirubin =\<1.5 x upper limit of normal (ULN) * Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =\< 3 x ULN * Absolute neutrophil count (ANC) \>= 1.0 x 10\^9/L * Hemoglobin \>= 8 g/dL * Platelet count \>= 75 x 10\^9/L * Calculated creatinine clearance (by Cockroft-Gault) \>= 50 ml/min or serum creatinine below 2 g/dL * Voluntary written consent must be given before performance of any study related procedure not part of standard medical care, with the understanding that consent may be withdrawn by the patient at any time without prejudice to future medical care * Female patients who: * Are postmenopausal for at least 1 year before the screening visit, OR * Are surgically sterile, OR * If they are of childbearing potential, agree to practice 2 effective methods of contraception, at the same time, from the time of signing the informed consent form through 90 days after the last dose of study drug, OR * Agree to practice true abstinence when this is in line with the preferred and usual lifestyle of the subject; (periodic abstinence \[e.g., calendar, ovulation, symptothermal, post-ovulation methods\] and withdrawal are not acceptable methods of contraception) * Male patients, even if surgically sterilized (i.e., status post-vasectomy), must agree to one of the following: * Agree to practice effective barrier contraception during the entire study treatment period and through 90 days after the last dose of study drug, OR * Agree to practice true abstinence when this is in line with the preferred and usual lifestyle of the subject; (periodic abstinence \[e.g., calendar, ovulation, symptothermal, post-ovulation methods\] and withdrawal are not acceptable methods of contraception) Exclusion Criteria: * Evidence of progressive disease on lenalidomide maintenance as per IMWG criteria * Patients who have already started or received multi-drug consolidation regimen post-transplant expect for lenalidomide maintenance * Diarrhea \> grade 1 in the absence of anti-diarrheals * Central nervous system involvement * Female patients who are lactating or have a positive serum pregnancy test during the screening period * History of allergy to mannitol * Major surgery within 14 days before enrollment * Radiotherapy within 14 days before randomization; if the involved field is small, 7 days will be considered a sufficient interval between treatment and administration of the ixazomib * Evidence of current uncontrolled cardiovascular conditions, including uncontrolled cardiac conditions such as hypertension, or cardiac arrhythmias, or New York Heart Association stage III and IV congestive heart failure, or unstable angina or myocardial infarction within the past 6 months * Rate-corrected QT interval of electrocardiograph (QTc) \> 470 msec on a 12-lead electrocardiogram (ECG) during screening * Uncontrolled diabetes * Acute infection requiring systemic anti-infectives, antivirals, or antifungals within two weeks prior to first dose * Systemic treatment, within 14 days before the first dose of ixazomib, with strong inhibitors of cytochrome P450 family 3, subfamily A, polypeptide 2 (CYP1A2) (fluvoxamine, enoxacin, ciprofloxacin), strong inhibitors of cytochrome P450 family 3, subfamily A CYP3A (clarithromycin, telithromycin, itraconazole, voriconazole, ketoconazole, nefazodone, posaconazole) or strong CYP3A inducers (rifampin, rifapentine, rifabutin, carbamazepine, phenytoin, phenobarbital), or use of Ginkgo biloba or St. John's wort * Ongoing or active systemic infection, active hepatitis B or C virus infection, or known human immunodeficiency virus (HIV) positive * Any serious medical or psychiatric illness that could, in the investigator's opinion, potentially interfere with the completion of treatment according to this protocol * Known allergy to any of the study medications, their analogues, or excipients in the various formulations of any agent * Known gastrointestinal (GI) disease or GI procedure that could interfere with the oral absorption or tolerance of ixazomib including difficulty swallowing * Diagnosed or treated for another malignancy within 2 years before study enrollment or previously diagnosed with another malignancy and have any evidence of residual disease; patients with nonmelanoma skin cancer or carcinoma in situ of any type are not excluded if they have undergone complete resection * Patient has \>= grade 3 peripheral neuropathy, or grade 2 with pain on clinical examination during the screening period * Participation in other clinical trials, including those with other investigational agents not included in this trial, within 30 days of the start of this trial and throughout the duration of this trial
healthy Volunteers
false
minimum Age
18 Years
sex
ALL
std Ages
  1. ADULT
  2. OLDER_ADULT
Treatment arms and interventions
arm Groups
  1. description
    Patients receive ixazomib citrate PO on days 1, 8, and 15, lenalidomide PO QD on days 1-21, and dexamethasone PO on days 1, 8, 15, and 22 (of courses 1-4 only).
    intervention Names
    1. Drug: Ixazomib Citrate
    2. Drug: Lenalidomide
    3. Drug: Dexamethasone
    label
    Arm I (ixazomib citrate, lenalidomide, dexamethasone)
    type
    EXPERIMENTAL
  2. description
    Patients receive lenalidomide PO as in Arm I.
    intervention Names
    1. Drug: Lenalidomide
    label
    Arm II (lenalidomide)
    type
    ACTIVE_COMPARATOR
interventions
  1. arm Group Labels
    1. Arm I (ixazomib citrate, lenalidomide, dexamethasone)
    description
    Given PO
    name
    Ixazomib Citrate
    other Names
    1. MLN-9708
    2. MLN9708
    3. proteasome inhibitor MLN9708
    type
    DRUG
  2. arm Group Labels
    1. Arm I (ixazomib citrate, lenalidomide, dexamethasone)
    2. Arm II (lenalidomide)
    description
    Given PO
    name
    Lenalidomide
    other Names
    1. CC-5013
    2. CC5013
    3. CDC 501
    4. IMiD-1
    type
    DRUG
  3. arm Group Labels
    1. Arm I (ixazomib citrate, lenalidomide, dexamethasone)
    description
    Given PO
    name
    Dexamethasone
    other Names
    1. DM
    type
    DRUG
Study design
allocation
RANDOMIZED
intervention Model
PARALLEL
masking Info
masking
NONE
primary Purpose
TREATMENT
Enrollment
count
42
type
ACTUAL
Registered outcome plans (not posted results)
primary Outcomes
  1. description
    Rate of MRD negativity after 12 months of treatment with Ixazomib in combination with lenalidomide and dexamethasone compared to MRD negativity rate after 12 months of lenalidomide alone. For the majority of patients, where MRD positivity at screening will be determined by Multi-parameter Flow Cytometry (MFC), an improvement will be defined as a conversion from MRD-positive to MRD-negative disease by MFC. Additionally, in the fraction of patients with MRD-negative disease by MFC at screening, who were MRD-positive by Next Generation Sequencing (NGS), an improvement will be defined as a conversion from MRD-positive to MRD-negative disease by NGS
    measure
    Percentage of Participants With MRD Negativity
    time Frame
    At 12 months
secondary Outcomes
  1. description
    Overall response was defined according to IMWG criteria as 1. very good partial response (VGPR) 2. complete response (CR) 3. stringent complete response (sCR)
    measure
    Overall Response (Number of Participants With VGPR, CR, sCR)
    time Frame
    At 6 months
  2. description
    Duraion of MRD-negativie disease was defined as the duration from the date of MRD negative to the date of diseae progression or date of last clinical follow up.
    measure
    Duration of MRD-negative Disease
    time Frame
    every 28 days, up to 2 years
  3. description
    Time to event will be estimated using the product-limit method of Kaplan and Meier.
    measure
    Progression Free Survival
    time Frame
    up to 2 years
  4. description
    OS is the time from randomization date to death date. Participants who have not died will be censored on the last date they are known to be alive.
    measure
    Overall Survival
    time Frame
    Up to 2 years
  5. description
    Graded by the National Cancer Institute Common Terminology Criteria for Adverse Events version 4.0
    measure
    Number of Patients With Adverse Events
    time Frame
    Up to 30 days post-treatment, **up to 2 years**
  6. description
    Overall response was defined according to IMWG criteria as 1. very good partial response (VGPR) 2. complete response (CR) 3. stringent complete response (sCR)
    measure
    Overall Response (Number of Participants With VGPR, CR, sCR)
    time Frame
    At 12 months
Full study description
brief Summary
This randomized phase II trial studies how well lenalidomide alone compared to lenalidomide, ixazomib citrate, and dexamethasone work in treating patients with multiple myeloma that remains (residual) after donor stem cell transplant. Lenalidomide may help the immune system kill abnormal blood cells or cancer cells and may also prevent the growth of new blood vessels that are needed for cancer growth. Ixazomib citrate may stop the growth of cancer cells by interfering with proteins necessary for cell growth. Drugs used in chemotherapy, such as dexamethasone, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. It is not yet known whether lenalidomide is more effective with or without ixazomib citrate and dexamethasone in treating residual multiple myeloma.
detailed Description
PRIMARY OBJECTIVES: I. To determine the rate of minimal residual disease (MRD)-negative disease by multiparameter-flow cytometry at 12 months after randomization. SECONDARY OBJECTIVES: I. Evidence of response as demonstrated by the improvement of the depth of response by at least one category according to International Myeloma Working Group (IMWG) response criteria. II. Progression free survival (PFS). III. Overall survival (OS). IV. Duration of MRD-negative disease. V. Safety and tolerability of experimental arm (ixazomib citrate, lenalidomide, and low dose dexamethasone \[IRd\]) vs. control arm (lenalidomide \[Rd\]). TERTIARY OBJECTIVES: I. Determination of markers of response based on pre-treatment characteristics using methods described in correlative research. II. Evaluation of MRD by gene sequencing method using the Sequenta platform (LymphoSIGHT®) in parallel with multi-parameter flow cytometry (MFC). OUTLINE: Patients are randomized to 1 of 2 treatment arms. ARM I: Patients receive ixazomib citrate orally (PO) on days 1, 8, and 15, lenalidomide PO once daily (QD) on days 1-21, and dexamethasone PO on days 1, 8, 15, and 22 (of courses 1-4 only). ARM II: Patients receive lenalidomide PO as in Arm I. In both arms, treatment repeats every 28 days for 12 courses in the absence of disease progression or unacceptable toxicity. After the completion of treatment, patients are followed up at 30 days and then every 3 months for 2 years.
Source references
Source notices and limitations
    Discovery and provenance
    1. release id
      ctgov-registry-1336d216cbd1bbff780dac70
      edge id
      nct-edge-3890e44f465cb620db08
      requested nct id
      NCT02389517
      primary nct id
      NCT02389517
      source kind
      ctgov_condition_query
      source record id
      Source null
      source file sha256
      2314ce01316b2d7044d298c6d25eda12e99cc5f44273bc75efed6cd5e03a8c14
      payload sha256
      1655ec5f33b36c52ea84ff043cc1315806b3c3d2d3128e96566f55be61526303
      payload
      clinical indication matching status
      condition_index_match_asserted_by_registry_not_reviewed
      end exclusive
      true
      id
      nct-edge-3890e44f465cb620db08
      link basis
      returned_by_explicit_condition_and_posted_results_filter_query
      nct id
      NCT02389517
      occurrences
      1. context exact
        NCT02389517
        end
        11
        exact text
        NCT02389517
        start
        0
      offset unit
      unicode_code_points
      query cond
      Plasma Cell Neoplasms
      query disease state id
      ds-plasma-cell-neoplasms
      source file
      /Users/arunverma/Documents/ChatGPT/Cancer Statistics Website/research-data/2026-09-10/clinicaltrials-condition/round-0000/raw/cond-plasma-cell-neoplasms-000.json
      source file sha256
      2314ce01316b2d7044d298c6d25eda12e99cc5f44273bc75efed6cd5e03a8c14
      source json pointer
      /studies/414/protocolSection/identificationModule/nctId
      source kind
      ctgov_condition_query
      source record id
      Source null
      source string basis
      parsed_JSON_string_unmodified
      source string sha256
      9afc00bcbd3fdfd62f830e6e0fd93edf0b9ce72411951787ba1d987de57c7a1b

    Preserved source evidence · Not medical advice